Final analyses of the prospective controlled trial on the efficacy of uracil and tegafur/leucovorin as an adjuvant treatment for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC46-1201).
Adjuvant chemotherapy
Colon cancer
High-risk stage II
Inverse probability of treatment-weighting
Leucovorin
Propensity score
Risk factor
Tegafur
Uracil
Journal
International journal of clinical oncology
ISSN: 1437-7772
Titre abrégé: Int J Clin Oncol
Pays: Japan
ID NLM: 9616295
Informations de publication
Date de publication:
04 Jun 2024
04 Jun 2024
Historique:
received:
15
04
2024
accepted:
28
05
2024
medline:
4
6
2024
pubmed:
4
6
2024
entrez:
4
6
2024
Statut:
aheadofprint
Résumé
The efficacy of adjuvant chemotherapy for high-risk stage II colon cancer (CC) has not been well established. Using propensity score matching, we previously reported that the 3-year disease-free survival (DFS) rate was significantly higher in patients treated with uracil and tegafur plus leucovorin (UFT/LV) against surgery alone. We report the final results, including updated 5-year overall survival (OS) rates and risk factor analysis outcomes. In total, 1902 high-risk stage II CC patients with T4, perforation/penetration, poorly differentiated adenocarcinoma/mucinous carcinoma, and/or < 12 dissected lymph nodes were enrolled in this prospective, non-randomized controlled study based on their self-selected treatment. Oral UFT/LV therapy was administered for six months after surgery. Of the 1880 eligible patients, 402 in Group A (surgery alone) and 804 in Group B (UFT/LV) were propensity score-matched. The 5-year DFS rate was significantly higher in Group B than in Group A (P = 0.0008). The 5-year OS rates were not significantly different between groups. The inverse probability of treatment weighting revealed significantly higher 5-year DFS (P = 0.0006) and 5-year OS (P = 0.0122) rates in group B than in group A. Multivariate analyses revealed that male sex, age ≥ 70 years, T4, < 12 dissected lymph nodes, and no adjuvant chemotherapy were significant risk factors for DFS and/or OS. The follow-up data from our prospective non-randomized controlled study revealed a considerable survival advantage in DFS offered by adjuvant chemotherapy with UFT/LV administered for six months over surgery alone in individuals with high-risk stage II CC. Japan Registry of Clinical Trials: jRCTs031180155 (date of registration: 25/02/2019), UMIN Clinical Trials Registry: UMIN000007783 (date of registration: 18/04/2012).
Sections du résumé
BACKGROUND
BACKGROUND
The efficacy of adjuvant chemotherapy for high-risk stage II colon cancer (CC) has not been well established. Using propensity score matching, we previously reported that the 3-year disease-free survival (DFS) rate was significantly higher in patients treated with uracil and tegafur plus leucovorin (UFT/LV) against surgery alone. We report the final results, including updated 5-year overall survival (OS) rates and risk factor analysis outcomes.
METHODS
METHODS
In total, 1902 high-risk stage II CC patients with T4, perforation/penetration, poorly differentiated adenocarcinoma/mucinous carcinoma, and/or < 12 dissected lymph nodes were enrolled in this prospective, non-randomized controlled study based on their self-selected treatment. Oral UFT/LV therapy was administered for six months after surgery.
RESULTS
RESULTS
Of the 1880 eligible patients, 402 in Group A (surgery alone) and 804 in Group B (UFT/LV) were propensity score-matched. The 5-year DFS rate was significantly higher in Group B than in Group A (P = 0.0008). The 5-year OS rates were not significantly different between groups. The inverse probability of treatment weighting revealed significantly higher 5-year DFS (P = 0.0006) and 5-year OS (P = 0.0122) rates in group B than in group A. Multivariate analyses revealed that male sex, age ≥ 70 years, T4, < 12 dissected lymph nodes, and no adjuvant chemotherapy were significant risk factors for DFS and/or OS.
CONCLUSION
CONCLUSIONS
The follow-up data from our prospective non-randomized controlled study revealed a considerable survival advantage in DFS offered by adjuvant chemotherapy with UFT/LV administered for six months over surgery alone in individuals with high-risk stage II CC.
TRIAL REGISTRATION
BACKGROUND
Japan Registry of Clinical Trials: jRCTs031180155 (date of registration: 25/02/2019), UMIN Clinical Trials Registry: UMIN000007783 (date of registration: 18/04/2012).
Identifiants
pubmed: 38833114
doi: 10.1007/s10147-024-02565-5
pii: 10.1007/s10147-024-02565-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Sung H, Ferlay J, Siegel R et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249
pubmed: 33538338
National comprehensive cancer network. (2014) Clinical practice guidelines in oncology (NCCN Guidelines®). Colon Cancer. Version 2.2015 http://www2.tri-kobe.org/nccn/guideline/archive/colorectal2015/english/colon.pdf
Benson AB 3rd, Schrag D, Somerfield MR et al (2004) American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408–3419
pubmed: 15199089
Schmoll HJ, Van Cutsem E, Stein A et al (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23:2479–2516
pubmed: 23012255
Costas-Chavarri A, Nandakumar G, Temin S et al (2019) Treatment of patients with early-stage colorectal cancer: ASCO resource-stratified guideline. J Glob Oncol 5:1–19
pubmed: 30802159
Hashiguchi Y, Muro K, Saito Y et al (2020) Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol 25:1–42
pubmed: 31203527
Schippinger W, Samonigg H, Schaberl-Moser R et al (2007) A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. Br J Cancer 97:1021–1027
pubmed: 17895886
pmcid: 2360441
Eheman CR, O’Neil ME, Styles TS et al (2016) Use of adjuvant chemotherapy among stage II colon cancer patients in 10 population-based national program of cancer registries. J Registry Manag 43:179–186
pubmed: 29308117
Compton CC, Fielding LP, Burgart LJ et al (2000) Prognostic factors in colorectal cancer. College of American pathologists consensus statement 1999. Arch Pathol Lab Med 124:979–994
pubmed: 10888773
Amri R, England J, Bordeianou LG et al (2016) Risk stratification in patients with stage II colon cancer. Ann Surg Oncol 23:3907–3914
pubmed: 27380640
O’Connor ES, Greenblatt DY, LoConte NK et al (2011) Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 29:3381–3388
pubmed: 21788561
pmcid: 3164243
Tournigand C, Andre T, Bonnetain F et al (2012) Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the multicenter international study of oxaliplatin, fluorouracil, and leucovorin in the adjuvant treatment of colon cancer trial. J Clin Oncol 30:3353–3360
pubmed: 22915656
Lembersky BC, Wieand HS, Petrelli NJ et al (2006) Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from national surgical adjuvant breast and bowel project protocol C-06. J Clin Oncol 24:2059–2064
pubmed: 16648506
Kopec JA, Yothers G, Ganz PA et al (2007) Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from national surgical adjuvant breast and bowel project trial C-06. J Clin Oncol 25:424–430
pubmed: 17264338
Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70:41–55
Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:3083–3107
pubmed: 19757444
pmcid: 3472075
Sadahiro S, Sakamoto K, Tsuchiya T et al (2022) Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201). BMC Cancer 22:170
pubmed: 35168560
pmcid: 8845390
Sugimoto K, Sakamoto K, Tsuchiya T et al (2023) Prognostic factors in patients with high-risk stage II colon cancer after curative resection: a post hoc analysis of the JFMC46-1201 trial. Int J Colorectal Dis 38:260
pubmed: 37903983
pmcid: 10615946
Sadahiro S, Morita S, Sasaki K et al (2015) Treatment rationale and study design for clinical trial on the efficacy of UFT/LV for stage II colorectal cancer with risk factors for recurrence (JFMC46-1201). Clin Colorectal Cancer 14:277–280
pubmed: 26068602
Robins JM, Hernan MA, Brumback B (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11:550–560
pubmed: 10955408
Stefanski LA, Boos DD (2002) The calculus of m-estimation. Am Stat 56:29–38
Sargent DJ, Wieand HS, Haller DG et al (2005) Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23:8664–8670
pubmed: 16260700
O’Connell MJ, Campbell ME, Goldberg RM et al (2008) Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. J Clin Oncol 26:2336–2341
pubmed: 18467725
You XH, Jiang YH, Fang Z et al (2020) Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials. ESMO Open. https://doi.org/10.1136/esmoopen-2019-000605
doi: 10.1136/esmoopen-2019-000605
pubmed: 32132090
pmcid: 7064070
Mody K, Bekaii-Saab T (2018) Clinical trials and progress in metastatic colon cancer. Surg Oncol Clin N Am 27:349–365
pubmed: 29496094
de Gramont A, Hubbard J, Shi Q et al (2010) Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol 28:460–465
pubmed: 20008641
Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351
pubmed: 15175436
Matsuda C, Ishiguro M, Teramukai S et al (2018) A randomised-controlled trial of 1-year adjuvant chemotherapy with oral tegafur-uracil versus surgery alone in stage II colon cancer: SACURA trial. Eur J Cancer 96:54–63
pubmed: 29677641
Andre T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116
pubmed: 19451431
Malik YG, Benth JS, Hamre HM et al (2024) Chemotherapy reduces long-term quality of life in recurrence-free colon cancer survivors (LaTE study)-a nationwide inverse probability of treatment-weighted registry-based cohort study and survey. Colorectal Dis 26:22–33
pubmed: 38036898
Ribic CM, Sargent DJ, Moore MJ et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349:247–257
pubmed: 12867608
pmcid: 3584639
Saridaki Z, Souglakos J, Georgoulias V (2014) Prognostic and predictive significance of MSI in stages II/III colon cancer. World J Gastroenterol 20:6809–6814
pubmed: 24944470
pmcid: 4051919